Syngenta and Novozymes to partner for phosphate use efficiency
Apr 25, 2012, 02:00 ET
BASEL, Switzerland, April 25, 2012 /PRNewswire/ --
- Exclusive expansion into new markets for JumpStart
- Integrated offer with Seed Care
- Sustainable solution for growers
Syngenta and Novozymes today announced a global agreement under which Syngenta will work with Novozymes to commercialize the Novozymes technology JumpStart, a seed-applied biological which increases phosphate solubility in the soil. The two companies will jointly develop the market for JumpStart in combination with Syngenta's Seed Care portfolio on crops including cereals and corn. The agreement extends the geographic potential of JumpStart, currently sold mainly in North America, to the rest of the world.
Phosphorus is an essential macronutrient for the healthy growth of young plants. JumpStart is based on a unique fungus Penicillium bilaii, which increases phosphate uptake into the plant through the root system. The market potential for seed-applied technologies to increase phosphate efficiency is estimated at over $100 million.
John Atkin, COO Syngenta, said: "We are pleased to enter into this agreement with Novozymes which marks a further addition to our growing range of bioactives. Our Seed Care portfolio already offers best-in-class control of insects and disease together with crop enhancement benefits. With the addition of JumpStart, growers will now gain the added advantage of improved phosphate efficiency."
Thomas Videbaek, Executive Vice President Novozymes, commented: "Partnering with Syngenta supports our strategic goal to provide the world with natural and biological solutions to help farmers worldwide increase yields to feed the world's growing population."
Syngenta is one of the world's leading companies with more than 26,000 employees in over 90 countries dedicated to our purpose: Bringing plant potential to life. Through world-class science, global reach and commitment to our customers we help to increase crop productivity, protect the environment and improve health and quality of life. For more information about us please go to www.syngenta.com
| Cautionary Statement Regarding Forward-Looking Statements
This document contains forward-looking statements, which can be identified by terminology such as 'expect', 'would', 'will', 'potential', 'plans', 'prospects', 'estimated', 'aiming', 'on track' and similar expressions. Such statements may be subject to risks and uncertainties that could cause the actual results to differ materially from these statements. We refer you to Syngenta's publicly available filings with the U.S. Securities and Exchange Commission for information about these and other risks and uncertainties. Syngenta assumes no obligation to update forward-looking statements to reflect actual results, changed assumptions or other factors. This document does not constitute, or form part of, any offer or invitation to sell or issue, or any solicitation of any offer, to purchase or subscribe for any ordinary shares in Syngenta AG, or Syngenta ADSs, nor shall it form the basis of, or be relied on in connection with, any contract therefor. |
| Syngenta International AG |
Media contact: |
Analyst/Investor contacts: |
| Media Office |
Medard Schoenmaeckers |
Jennifer Gough |
| CH-4002 Basel |
Switzerland +41 61 323 2323 |
Switzerland +41 61 323 5059 |
| Switzerland |
USA +1 202 737 6521 |
|
| Tel: +41 61 323 23 23 |
||
| Fax: +41 61 323 24 24 |
||
SOURCE Syngenta
Share this article